Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Am J Hematol
    May 2024
  1. SHOMALI W, Gotlib J
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:946-968.
    >> Share

  2. CIUREA SO, Kongtim P, Srour S, Chen J, et al
    Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
    Am J Hematol. 2024;99:890-899.
    >> Share

  3. ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
    Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
    Am J Hematol. 2024;99:862-870.
    >> Share

  4. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
    Am J Hematol. 2024;99:806-815.
    >> Share

    April 2024
  5. YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al
    Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the Europea
    Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342.
    >> Share

  6. ZHOU Z, Zhuo N, Zhou Y, Sun C, et al
    Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
    Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340.
    >> Share

  7. SZUBER N, Orazi A, Tefferi A
    Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321.
    >> Share

  8. SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
    Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
    Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
    >> Share

  9. CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al
    Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
    Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304.
    >> Share

  10. MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al
    Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature.
    Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308.
    >> Share

  11. KHAN AA, James D, Andresen V, Atkey J, et al
    Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
    Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301.
    >> Share

  12. LITZOW MR
    Building a better blinatumomab.
    Am J Hematol. 2024;99:512-514.
    >> Share

  13. HU S, Jabbour EJ, Hu CY, Tang G, et al
    Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
    Am J Hematol. 2024;99:721-726.
    >> Share

    March 2024
  14. HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
    The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia.
    Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.
    >> Share

  15. TANG H, Jia W, Jia S, Dong R, et al
    A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
    >> Share

  16. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271.
    >> Share

  17. TROUSSARD X, Maitre E, Paillassa J
    Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240.
    >> Share

    February 2024
  18. MIRVIS E, Sairam S, Vainieri E, Tona F, et al
    Pituitary apoplexy in acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277.
    >> Share

  19. JIANG M, Wang X, Yu M, Jiang S, et al
    Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272.
    >> Share

  20. SANDBERG Y, Budel LM, Bain BJ
    Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so simple.
    Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268.
    >> Share

  21. GANGAT N, Tefferi A
    Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Am J Hematol. 2024 Feb 20. doi: 10.1002/ajh.27256.
    >> Share

  22. BATALLER A, DiNardo CD, Bazinet A, Daver NG, et al
    Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27236.
    >> Share

  23. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
    Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
    >> Share

  24. PRATZ KW, Jonas BA, Pullarkat V, Thirman MJ, et al
    Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27246.
    >> Share

  25. AUTORE F, Visentin A, Deodato M, Vitale C, et al
    Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247.
    >> Share

  26. ABAZA Y, Winer ES, Murthy GSG, Shallis RM, et al
    Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27231.
    >> Share

  27. CHEN X, Yuan L, Zhang Y, Wang F, et al
    Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
    Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249.
    >> Share

  28. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    >> Share

  29. HORNAK T, Mayer J, Cicatkova P, Semerad L, et al
    De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229.
    >> Share

  30. BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al
    Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232.
    >> Share

  31. KURITA N, Imahashi N, Chiba S, Tanaka M, et al
    Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
    Am J Hematol. 2024;99:236-244.
    >> Share

  32. GURNARI C, Pascale MR, Vitale A, Diral E, et al
    Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
    Am J Hematol. 2024;99:254-262.
    >> Share

  33. DINARDO CD
    Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    Am J Hematol. 2024;99:152-154.
    >> Share

  34. BRUNNER AM, Esteve J, Porkka K, Knapper S, et al
    Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
    Am J Hematol. 2024;99:E32-E36.
    >> Share

    January 2024
  35. CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al
    Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218.
    >> Share

  36. IM A, Quann K, Agha M, Raptis A, et al
    Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
    Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212.
    >> Share

  37. VARDELL VA, Ermann DA, Fitzgerald L, Shah H, et al
    T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
    Am J Hematol. 2024 Jan 19. doi: 10.1002/ajh.27205.
    >> Share


  38. Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
    Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
    >> Share

  39. BARON F, Efficace F, Cannella L, Stevens-Kroef M, et al
    Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
    Am J Hematol. 2024 Jan 4. doi: 10.1002/ajh.27196.
    >> Share

  40. MOUKALLED N, Labopin M, Versluis J, Socie G, et al
    Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Le
    Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27187.
    >> Share

  41. PELLAND-MARCOTTE MC, Kulkarni K, Tran TH, Stammers D, et al
    Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
    Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27171.
    >> Share

  42. SPONSEILER I, Bandian AM, Pusic P, Lion T, et al
    Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
    Am J Hematol. 2024;99:E9-E11.
    >> Share

  43. TEFFERI A, Abdelmagid M, Al-Kali A, Patnaik M, et al
    Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
    Am J Hematol. 2024;99:21-27.
    >> Share

    December 2023
  44. MOLICA S, Shanafelt TD, Allsup D, Giannarelli D, et al
    Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
    Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27182.
    >> Share

  45. KARRAR O, Abdelmagid M, Rana M, Iftikhar M, et al
    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
    Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27180.
    >> Share

  46. GANGAT N, Karrar O, Iftikhar M, McCullough K, et al
    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
    Am J Hematol. 2023 Dec 10. doi: 10.1002/ajh.27138.
    >> Share

  47. JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al
    The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
    Am J Hematol. 2023;98:E364-E368.
    >> Share

  48. OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al
    Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
    Am J Hematol. 2023;98:1909-1922.
    >> Share

    November 2023
  49. VALENT P
    Clinical impact of cytomorphology in mast cell leukemia.
    Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27146.
    >> Share

    October 2023
  50. GHERGUS D, Martin M, Knapp AM, Delmotte F, et al
    Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
    Am J Hematol. 2023 Oct 19. doi: 10.1002/ajh.27137.
    >> Share

  51. SALIBA RM, Kanakry CG, Gadalla S, Kebriaei P, et al
    Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.
    Am J Hematol. 2023 Oct 18. doi: 10.1002/ajh.27126.
    >> Share

  52. KITTAI AS, Skarbnik A, Miranda M, Yong ASM, et al
    A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
    Am J Hematol. 2023 Oct 9. doi: 10.1002/ajh.27110.
    >> Share

  53. ZHANG L, Yang X, Ge X, Li B, et al
    CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27108.
    >> Share

  54. SUNG MT, Chen LH, Chiang YW, Jhuang JY, et al
    Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor-derived myelodysplastic syndrome using single-cell multi-omics analysis.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27121.
    >> Share

  55. HAZARIKA B, Bain BJ
    Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27114.
    >> Share

  56. HIRABAYASHI S, Kondo T, Nishiwaki S, Mizuta S, et al
    Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph(+) ALL: A retrospective nationwide study.
    Am J Hematol. 2023;98:1606-1618.
    >> Share

  57. CALABRESI L, Carretta C, Romagnoli S, Rotunno G, et al
    Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
    Am J Hematol. 2023;98:1520-1531.
    >> Share


  58. Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
    Am J Hematol. 2023;98 Suppl 5:S3-S57.
    >> Share

    September 2023
  59. VISENTIN A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, et al
    The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
    Am J Hematol. 2023 Sep 29. doi: 10.1002/ajh.27093.
    >> Share

  60. HADDAD FG, Short NJ
    Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
    Am J Hematol. 2023 Sep 27. doi: 10.1002/ajh.27100.
    >> Share

  61. ZHANG X, Yang J, Li J, Qiu L, et al
    Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
    >> Share

  62. TEFFERI A, Pardanani A, Al-Kali A, Alkhateeb H, et al
    Mast cell cytomorphology and treatment outcome in mast cell leukemia.
    Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27105.
    >> Share

  63. ANIL J, Alnemri A, Lytle A, Lockhart B, et al
    Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.
    Am J Hematol. 2023 Sep 18. doi: 10.1002/ajh.27098.
    >> Share

  64. VON ASMUTH EGJ, Lankester AC, Putter H
    Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
    Am J Hematol. 2023 Sep 15. doi: 10.1002/ajh.27083.
    >> Share

  65. PATEL PC, Ball S, Jain AG, Wang C, et al
    Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
    Am J Hematol. 2023 Sep 13. doi: 10.1002/ajh.27092.
    >> Share

  66. PARDANANI A, Tefferi A, Al-Kali A, Patnaik M, et al
    Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
    Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27089.
    >> Share

  67. NATH K, Lee J, Elko TA, Levy L, et al
    Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
    Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27084.
    >> Share

  68. FANG H, Medeiros LJ, Wang W
    Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?
    Am J Hematol. 2023 Sep 8. doi: 10.1002/ajh.27085.
    >> Share

  69. RAVANDI F, Cloos J, Buccisano F, Dillon R, et al
    Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
    Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27087.
    >> Share

  70. ZHOU JY, Wang S, Yuan HL, Xu YJ, et al
    Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.
    Am J Hematol. 2023;98:1394-1406.
    >> Share

  71. TEFFERI A, Barbui T
    Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:1465-1487.
    >> Share

    August 2023
  72. ZAMBROTTA GPM, Nicolini FE, Assouline S, Busque L, et al
    Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
    Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27073.
    >> Share

  73. KADIA TM, Ravandi F, Molica M, Bataller A, et al
    Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
    Am J Hematol. 2023 Aug 27. doi: 10.1002/ajh.27054.
    >> Share

  74. KOSYDAR SR, Parikh SA, Lester SC, Rabe KG, et al
    Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment.
    Am J Hematol. 2023 Aug 24. doi: 10.1002/ajh.27060.
    >> Share

  75. GARCIA-MANERO G
    Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:1307-1325.
    >> Share

  76. WANG SA, Orazi A, Gotlib J, Reiter A, et al
    The international consensus classification of eosinophilic disorders and systemic mastocytosis.
    Am J Hematol. 2023;98:1286-1306.
    >> Share

  77. ZINI G, Bennett JM
    ICC-2022 versus WHO-2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists.
    Am J Hematol. 2023;98:E209-E211.
    >> Share

  78. SHORT NJ, Jabbour E, Macaron W, Ravandi F, et al
    Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
    Am J Hematol. 2023;98:1196-1203.
    >> Share

  79. JELLOUL FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, et al
    DDX41 mutations in patients with non-myeloid hematologic neoplasms.
    Am J Hematol. 2023;98:E193-E196.
    >> Share

    July 2023
  80. HADDAD FG, Sasaki K, Bidikian A, Issa GC, et al
    Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
    Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27037.
    >> Share

  81. BRADY MT, Laniewski N, Strawderman M, Chu CC, et al
    Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
    Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27038.
    >> Share

  82. ZUNA J, Hovorkova L, Krotka J, Winkowska L, et al
    Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
    Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27022.
    >> Share

  83. LOSCOCCO GG, Ascani S, Mannelli F, Zanelli M, et al
    Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
    Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026.
    >> Share

  84. PARDANANI A
    Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
    Am J Hematol. 2023;98:1097-1116.
    >> Share

  85. FALINI B, Martelli MP, Brunetti L, Gjertsen BT, et al
    The NPM1 mutant defines AML irrespective of blast count.
    Am J Hematol. 2023;98:E187-E189.
    >> Share

    June 2023
  86. VISENTIN A, Mauro FR, Scarfo L, Gentile M, et al
    Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
    Am J Hematol. 2023 Jun 29. doi: 10.1002/ajh.27009.
    >> Share

  87. NAKA R, Kondo T, Nishikubo M, Muranushi H, et al
    Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
    Am J Hematol. 2023 Jun 28. doi: 10.1002/ajh.27012.
    >> Share

  88. KANTARJIAN HM, Tefferi A
    Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress.
    Am J Hematol. 2023 Jun 26. doi: 10.1002/ajh.27007.
    >> Share

  89. HORST HA, Zugmaier G, Martinelli G, Mergen N, et al
    CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.
    Am J Hematol. 2023 Jun 22. doi: 10.1002/ajh.26988.
    >> Share

  90. BAZINET A, Kantarjian H, Arani N, Popat U, et al
    Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
    Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26997.
    >> Share

  91. MATTHEWS AH, Perl AE, Luger SM, Gill SI, et al
    Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
    Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26991.
    >> Share

  92. FALINI B
    NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Am J Hematol. 2023 Jun 15. doi: 10.1002/ajh.26989.
    >> Share

  93. SALIBA AN, Foa R
    Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing.
    Am J Hematol. 2023 Jun 14. doi: 10.1002/ajh.26993.
    >> Share

  94. JADI O, Tang H, Olsen K, Vensko S, et al
    Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2023;98:940-950.
    >> Share

  95. TANG Y, Zhang Z, Liu S, Yao Y, et al
    Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
    Am J Hematol. 2023;98:881-889.
    >> Share

  96. FENU EM, Margolskee E, Pillai V
    Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.
    Am J Hematol. 2023 Jun 1. doi: 10.1002/ajh.26983.
    >> Share

    May 2023
  97. GIRARD S, Lours C
    Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
    Am J Hematol. 2023 May 25. doi: 10.1002/ajh.26969.
    >> Share

  98. ROTBAIN EC, Allmer C, Rostgaard K, Andersen MA, et al
    Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2023 May 22. doi: 10.1002/ajh.26964.
    >> Share

  99. ISHIDA H, Shimada H, Tanizawa A, Shimazu Y, et al
    Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
    Am J Hematol. 2023 May 12. doi: 10.1002/ajh.26959.
    >> Share

  100. DAVER NG, Iqbal S, Huang J, Renard C, et al
    Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
    Am J Hematol. 2023 May 4. doi: 10.1002/ajh.26941.
    >> Share

  101. YANG S, Zhang X, Gale RP, Du X, et al
    Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
    Am J Hematol. 2023 May 2. doi: 10.1002/ajh.26943.
    >> Share

  102. IVANOV D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, et al
    Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
    Am J Hematol. 2023;98:770-783.
    >> Share

  103. HUNTINGTON SF, Schuster SJ, Ding W, Koehler AB, et al
    DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
    Am J Hematol. 2023;98:739-749.
    >> Share

  104. MARCOUX C, Marin D, Ramdial J, AlAtrash G, et al
    Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.
    Am J Hematol. 2023;98:712-719.
    >> Share

    April 2023
  105. FAN BE, Chen DTY, Ponnudurai K, Abdul Latiff STB, et al
    Artificial intelligence generated leukemia cell images.
    Am J Hematol. 2023 Apr 29. doi: 10.1002/ajh.26942.
    >> Share

  106. VARDELL VA, Ermann DA, Fitzgerald LA, Shah HR, et al
    Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia.
    Am J Hematol. 2023 Apr 20. doi: 10.1002/ajh.26937.
    >> Share

  107. MORABITO F, Tripepi G, Mauro FR, Laurenti L, et al
    The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
    Am J Hematol. 2023 Apr 17. doi: 10.1002/ajh.26927.
    >> Share

  108. FALINI B, Martelli MP, Brunetti L
    Mutant NPM1: Nuclear export and the mechanism of leukemogenesis.
    Am J Hematol. 2023;98:550-552.
    >> Share

  109. HAMPEL PJ, Parikh SA
    BTKi bonanza in CLL/SLL: Sorting out the differences.
    Am J Hematol. 2023;98:556-559.
    >> Share

  110. TEFFERI A, Bacigalup A
    Blast phase myeloproliferative neoplasm: Transplant to the rescue.
    Am J Hematol. 2023;98:553-555.
    >> Share

  111. ORTI G, Gras L, Zinger N, Finazzi MC, et al
    Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantat
    Am J Hematol. 2023;98:628-638.
    >> Share

    March 2023
  112. ROSE A, Zhang L, Jain AG, Poovathukaran Babu A, et al
    Delineation of Clinical Course, Outcomes, and Prognostic Factors in Patients with T-cell Prolymphocytic Leukemia.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26918.
    >> Share

  113. BACHELOT A, Bouvier A, Riou J, Thepot S, et al
    Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: assessment of different risk scores.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26917.
    >> Share


  114. Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia".
    Am J Hematol. 2023 Mar 24. doi: 10.1002/ajh.26894.
    >> Share

  115. GIPE N, Leung N, Lasho T, Mangaonkar A, et al
    Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26902.
    >> Share

  116. ALDOSS I, Afkhami M, Yang D, Gu Z, et al
    High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia-Like Fusions.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26908.
    >> Share

  117. QIU KY, Wang JY, Huang LB, Li CG, et al
    Vincristine and Dexamethasone Pulses in Addition to Maintenance Therapy Among Pediatric Acute Lymphoblastic Leukemia(GD-ALL-2008): an Open-label, Multicentre, Randomized, Phase III Clinical Trial.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26910.
    >> Share

  118. DESIKAN SP, Senapati J, Jabbour E, Abuasab T, et al
    Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26907.
    >> Share

  119. KATODRITOU E, Kastritis E, Dalampira D, Delimpasi S, et al
    Improved Survival of Patients with Primary Plasma Cell Leukemia with VRd or Daratumumab-based Quadruplets: A Multicenter Study by the Greek Myeloma Study Group.
    Am J Hematol. 2023 Mar 4. doi: 10.1002/ajh.26891.
    >> Share

  120. LO MY, Tsai XC, Lin CC, Tien FM, et al
    Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Am J Hematol. 2023 Mar 2. doi: 10.1002/ajh.26892.
    >> Share

  121. YANG YT, Yao CY, Chiu PJ, Kao CJ, et al
    Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia.
    Am J Hematol. 2023 Mar 1. doi: 10.1002/ajh.26893.
    >> Share

    February 2023
  122. EPPERLA N, Zhao Q, Anghelina M, Neal J, et al
    Impact of sex on outcomes in patients with Hairy cell leukemia. An HCL Patient Data Registry analysis.
    Am J Hematol. 2023 Feb 20. doi: 10.1002/ajh.26881.
    >> Share

  123. BADAT M, Sivaguru G, Bain BJ
    Ophthalmic presentation of chronic myeloid leukemia in two adolescents.
    Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26884.
    >> Share

  124. LEE BJ, Griffin SP, Doh J, Kongtim P, et al
    Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26880.
    >> Share

  125. MEJIA SALDARRIAGA M, Alhomoud M, Roboz G, Allan JN, et al
    Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26878.
    >> Share

  126. ANTHERIEU G, Donzel M, Balme B, Traverse-Glehen A, et al
    Chronic myelomonocytic leukemia transdifferenciation landscape: from histiocytosis to blastic plasmacytoid dendritic cell neoplasm.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26876.
    >> Share

  127. ZEIDAN AM, Borate U, Pollyea DA, Brunner AM, et al
    A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
    Am J Hematol. 2023;98:272-281.
    >> Share

  128. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
    Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Am J Hematol. 2023;98:365-367.
    >> Share

    January 2023
  129. WALIA A, Prasad V
    Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
    Am J Hematol. 2023 Jan 28. doi: 10.1002/ajh.26867.
    >> Share

  130. KIM MS, Prasad V
    Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy.
    Am J Hematol. 2023 Jan 26. doi: 10.1002/ajh.26864.
    >> Share

  131. ALDOSS I, Shah BD, Park JH, Muffly L, et al
    Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853.
    >> Share

  132. XU W, Zhou K, Wang T, Yang S, et al
    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26826.
    >> Share

  133. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
    The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26852.
    >> Share

  134. WEI AH, Dohner H, Sayar H, Ravandi F, et al
    Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
    Am J Hematol. 2023 Jan 19. doi: 10.1002/ajh.26847.
    >> Share

  135. CANDONI A, Lazzarotto D, Papayannidis C, Piccini M, et al
    PROSPECTIVE MULTICENTER STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME OF 230 UNFIT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING FIRST-LINE THERAPY WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
    Am J Hematol. 2023 Jan 18. doi: 10.1002/ajh.26846.
    >> Share

  136. GIEBEL S, Labopin M, Schroeder T, Swoboda R, et al
    Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Pa
    Am J Hematol. 2023 Jan 10. doi: 10.1002/ajh.26825.
    >> Share

  137. AL-KALI A, Tibes R, Atherton P, Palmer J, et al
    A Phase II Study of Combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia with KIT Expression.
    Am J Hematol. 2023 Jan 9. doi: 10.1002/ajh.26831.
    >> Share

  138. BIDIKIAN A, Jabbour E, Issa GC, Short NJ, et al
    Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor.
    Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26836.
    >> Share

  139. GURU MURTHY GS, Logan BR, Bo-Subait S, Beitinjaneh A, et al
    Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
    Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26834.
    >> Share

  140. FALINI B, Martelli MP
    Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
    Am J Hematol. 2023 Jan 5. doi: 10.1002/ajh.26812.
    >> Share

  141. PATNAIK MM, Tefferi A
    Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26828.
    >> Share

  142. KANTARJIAN H, Short NJ, Jain N, Sasaki K, et al
    Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
    Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26816.
    >> Share

  143. MARTINO G, Quintini M, Martelli MP, Ascani S, et al
    Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia - aCML).
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26817.
    >> Share

  144. SHIMONY S, Stahl M, Stone RM
    Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26822.
    >> Share

  145. HAZARIKA B, Bain BJ
    Granular B lymphoblastic leukemia.
    Am J Hematol. 2023;98:210-211.
    >> Share

  146. THIELE J, Kvasnicka HM, Orazi A, Gianelli U, et al
    The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
    Am J Hematol. 2023;98:166-179.
    >> Share

  147. LEE WH, Lin CC, Tsai CH, Tien FM, et al
    Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26799.
    >> Share

  148. GRAF I, Greiner G, Marculescu R, Gleixner KV, et al
    N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26805.
    >> Share

  149. LIU H, Huang F, Zhang Y, Wu M, et al
    Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26800.
    >> Share

    December 2022
  150. ARBER DA, Hasserjian RP, Orazi A
    Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia.
    Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26820.
    >> Share

  151. SENAPATI J, Abuasab T, Haddad FG, Ravandi F, et al
    Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
    Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26811.
    >> Share

  152. SALIBA AN, Foa R
    The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: giant strides and ongoing challenges.
    Am J Hematol. 2022 Dec 20. doi: 10.1002/ajh.26813.
    >> Share

  153. KWON A, Fuda F, Gagan J, John S, et al
    Rare circulating lymphoblasts with striking eosinophilia: A rare case of B lymphoblastic leukemia with PAX5::ZCCHC7.
    Am J Hematol. 2022 Dec 12. doi: 10.1002/ajh.26795.
    >> Share

  154. PASVOLSKY O, Saliba RM, Ledesma C, Popat UR, et al
    Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.
    Am J Hematol. 2022 Dec 11. doi: 10.1002/ajh.26789.
    >> Share

    November 2022
  155. RADICH J
    Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26790.
    >> Share

  156. WIECZOREK M, Labopin M, Castagna L, Brissot E, et al
    Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
    Am J Hematol. 2022 Nov 18. doi: 10.1002/ajh.26782.
    >> Share

  157. LEVI S, Bronstein Y, Goldschmidt N, Morabito F, et al
    Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26779.
    >> Share

  158. WOYACH JA
    Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Am J Hematol. 2022;97 Suppl 2:S11-S18.
    >> Share

  159. ARONSON JH, Skanland SS, Roeker LE, Thompson MC, et al
    Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
    Am J Hematol. 2022;97 Suppl 2:S19-S25.
    >> Share

  160. KUTSCH N, Fink AM, Fischer K
    Management of front line chronic lymphocytic leukemia.
    Am J Hematol. 2022;97 Suppl 2:S3-S10.
    >> Share

  161. CHIUSOLO P, Marchetti C, Rossi M, Minnella G, et al
    A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
    Am J Hematol. 2022;97:E400-E403.
    >> Share

  162. MCVINNIE K, Innes A, Nadal-Melsio E, Atta M, et al
    A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
    Am J Hematol. 2022;97:1491-1494.
    >> Share

    October 2022
  163. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
    Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
    Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.
    >> Share

  164. CHALANDON Y, Sbianchi G, Gras L, Koster L, et al
    Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
    Am J Hematol. 2022 Oct 20. doi: 10.1002/ajh.26764.
    >> Share

  165. STAHL M, Derkach A, Farnoud N, Bewersdorf JP, et al
    Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
    Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26757.
    >> Share

  166. WANG Q, Cai WZ, Wang QR, Zhu MQ, et al
    Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.
    Am J Hematol. 2022 Oct 11. doi: 10.1002/ajh.26758.
    >> Share

  167. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
    Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
    >> Share

  168. LANZA L, Koroveshi B, Barducchi F, Lorenzo A, et al
    A new diagnosis of monoclonal B-cell lymphocytosis with cytoplasmic inclusions in a patient with COVID-19.
    Am J Hematol. 2022;97:1372-1373.
    >> Share


  169. Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
    Am J Hematol. 2022;97 Suppl 3:S3-S40.
    >> Share

    September 2022
  170. RADKIEWICZ C, Bruchfeld JB, Weibull CE, Jeppesen ML, et al
    Sex differences in lymphoma incidence and mortality by subtype: a population-based study.
    Am J Hematol. 2022 Sep 30. doi: 10.1002/ajh.26744.
    >> Share

  171. RIVERA D, Kim K, Kanagal-Shamanna R, Borthakur G, et al
    Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.
    Am J Hematol. 2022 Sep 18. doi: 10.1002/ajh.26731.
    >> Share

  172. ZIPPER R, Fong V, Toker M, Reddy N, et al
    Neutrophilic Eccrine Hidradenitis in a pediatric patient with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 16. doi: 10.1002/ajh.26733.
    >> Share

  173. WRIGHT MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al
    Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.
    Am J Hematol. 2022 Sep 15. doi: 10.1002/ajh.26730.
    >> Share

  174. VENUGOPAL S, DiNardo CD, Loghavi S, Qiao W, et al
    Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26724.
    >> Share

  175. LEE BJ, Griffin SP, Doh J, Chan A, et al
    CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch.
    Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26713.
    >> Share

  176. FALINI B
    Acute myeloid leukemia risk models: Where do we stand?
    Am J Hematol. 2022;97:1124-1126.
    >> Share

    August 2022
  177. PRATZ KW, DiNardo CD, Selleslag D, Li J, et al
    Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A.
    Am J Hematol. 2022 Aug 30. doi: 10.1002/ajh.26692.
    >> Share

  178. JONAS BA, DiNardo C, Fracchiolla N, Pristupa A, et al
    Use of CYP3Ai and impact on outcomes in patients with AML treated with venetoclax plus azacitidine in the VIALE-A study.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26707.
    >> Share

  179. BORTHAKUR G, Ravandi F, Patel K, Wang X, et al
    Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD And
    Am J Hematol. 2022 Aug 26. doi: 10.1002/ajh.26700.
    >> Share

  180. SHORT NJ, Macaron W, Kadia T, Dinardo C, et al
    Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission.
    Am J Hematol. 2022 Aug 24. doi: 10.1002/ajh.26698.
    >> Share

  181. TEFFERI A, Begna KH, McCullough KB
    Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26695.
    >> Share

  182. LACHOWIEZ CA, Reville PK, Kantarjian H, Jabbour E, et al
    Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26694.
    >> Share

  183. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
    Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
    Am J Hematol. 2022 Aug 13. doi: 10.1002/ajh.26689.
    >> Share

  184. KANTARJIAN HM, Jabbour E, Deininger M, Abruzzese E, et al
    Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26686.
    >> Share

  185. SHAH MV, Chhetri R, Dholakia R, Kok CH, et al
    Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
    Am J Hematol. 2022;97:1013-1022.
    >> Share

    July 2022
  186. SHORT NJ, Kantarjian H
    Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions.
    Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26667.
    >> Share

  187. HERRMANN L, Bischof L, Backhaus D, Brauer D, et al
    Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26653.
    >> Share

  188. PETER B, Eisenwort G, Sadovnik I, Bauer K, et al
    BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph(+) Chronic Myeloid Leukemia.
    Am J Hematol. 2022 Jul 6. doi: 10.1002/ajh.26650.
    >> Share

  189. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
    Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
    Am J Hematol. 2022;97:E232-E235.
    >> Share

    June 2022
  190. ALCAZER V, Bonaventura P, Tonon L, Michel E, et al
    HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26647.
    >> Share

  191. NICHOLS ED, Jammal N, Chew S, Bryan J, et al
    Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
    Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26645.
    >> Share

  192. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26642.
    >> Share

  193. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
    Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
    >> Share

  194. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    >> Share

  195. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
    Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
    >> Share

  196. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
    Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
    >> Share

    May 2022
  197. PAUL S, Kantarjian H, Sasaki K, Marx K, et al
    Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 28. doi: 10.1002/ajh.26622.
    >> Share

  198. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
    Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
    >> Share

  199. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
    >> Share

  200. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
    Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
    Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
    >> Share

  201. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
    >> Share

  202. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
    Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.
    >> Share

  203. CHERNG HJ, Khwaja R, Kanagal-Shamanna R, Tang G, et al
    TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26595.
    >> Share

  204. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
    Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
    >> Share

  205. SINGH A, Al-Kali A, Begna KH, Litzow MR, et al
    Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Am J Hematol. 2022;97:630-637.
    >> Share

  206. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    >> Share

  207. GORDON MJ, Ferrajoli A
    Unusual complications in the management of chronic lymphocytic leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
    >> Share

    April 2022
  208. PEREZ-CARRETERO C, Hernandez-Sanchez M, Gonzalez T, Quijada-Alamo M, et al
    TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26578.
    >> Share

  209. KIM K, Konopleva M, DiNardo CD, Borthakur G, et al
    Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
    Am J Hematol. 2022 Apr 12. doi: 10.1002/ajh.26572.
    >> Share

  210. TANG B, Lee JB, Cheng S, Pan T, et al
    Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26564.
    >> Share

  211. SASAKI K, Ravandi F, Kadia T, DiNardo C, et al
    Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26557.
    >> Share

  212. INZOLI E, Aroldi A, Piazza R, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26556.
    >> Share

  213. LARSSON K, Soderling J, Hoglund M, Glimelius I, et al
    Cardiovascular disease in patients with chronic lymphocytic leukemia. A Swedish nationwide register study with matched comparators.
    Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26558.
    >> Share

  214. MCLAUGHLIN N, Ruan G, Day CN, Harmsen WS, et al
    A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
    Am J Hematol. 2022;97:E144-E147.
    >> Share

    March 2022
  215. HADDAD FG, Sasaki K, Issa GC, Garcia-Manero G, et al
    Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors.
    Am J Hematol. 2022 Mar 31. doi: 10.1002/ajh.26550.
    >> Share

  216. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    >> Share

  217. TORELLI GF, Chiaretti S, Peragine N, Barberi W, et al
    Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
    Am J Hematol. 2022 Mar 22. doi: 10.1002/ajh.26537.
    >> Share

  218. KRAKOW EF, Walter RB, Nathe JM, Perez T, et al
    Intensive Chemotherapy for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation.
    Am J Hematol. 2022 Mar 18. doi: 10.1002/ajh.26540.
    >> Share

  219. SMITH AC, Maze D, Xia D, Capo-Chichi JM, et al
    A t(6;14;9)(p22;q22;q34) Three-Way Translocation: Description of a Cytogenetically Visible Variant t(6;9) in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 16. doi: 10.1002/ajh.26534.
    >> Share

  220. GALLANT RE, Arroyo K, Bracci PM, Li S, et al
    Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26528.
    >> Share

  221. SHORT NJ, Macaron W, Konopleva M, Ravandi F, et al
    Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26526.
    >> Share

  222. KENNEDY VE, Hui G, Azenkot T, Gaut D, et al
    Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
    Am J Hematol. 2022 Mar 9. doi: 10.1002/ajh.26524.
    >> Share

  223. ORTIZ-MALDONADO V, Alonso-Saladrigues A, Espanol-Rego M, Martinez-Cibrian N, et al
    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26519.
    >> Share

    February 2022
  224. MOSHREF RAZAVI H, Yu R
    Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
    Am J Hematol. 2022 Feb 21. doi: 10.1002/ajh.26505.
    >> Share

  225. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    >> Share

  226. ARBER DA, Hasserjian RP, Orazi A, Mathews V, et al
    Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26503.
    >> Share

  227. BALL S, Jain AG, Aguirre LE, Al Ali N, et al
    Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26504.
    >> Share

  228. SHI M, Li L, Wang S, Cheng H, et al
    Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26506.
    >> Share

  229. MOLICA S, Giannarelli D, Visentin A, Reda G, et al
    Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26502.
    >> Share

  230. SENAPATI J, Shoukier M, Garcia-Manero G, Wang X, et al
    Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2022 Feb 12. doi: 10.1002/ajh.26496.
    >> Share

  231. POURHASSAN H, Yang D, Afkhami M, Pillai R, et al
    High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
    Am J Hematol. 2022 Feb 7. doi: 10.1002/ajh.26490.
    >> Share

  232. RACK K, De Bie J, Ameye G, Gielen O, et al
    Optimizing the Diagnostic Workflow for Acute Lymphoblastic Leukemia by Optical Genome Mapping.
    Am J Hematol. 2022 Feb 4. doi: 10.1002/ajh.26487.
    >> Share

  233. ALLSUP DJ, Craig Z, Cairns D, Howard D, et al
    Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26483.
    >> Share

  234. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    >> Share

  235. GAO F, Gao Y, Luo Y, Yu J, et al
    Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transpl
    Am J Hematol. 2022;97:E44-E47.
    >> Share

  236. KUNO M, Yamasaki S, Fujii N, Ishida Y, et al
    Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
    Am J Hematol. 2022;97:185-193.
    >> Share

    January 2022
  237. SZUBER N, Elliott M, Tefferi A
    Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
    Am J Hematol. 2022 Jan 28. doi: 10.1002/ajh.26481.
    >> Share

  238. LAZARIAN G, Theves F, Hormi M, Letestu R, et al
    TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
    Am J Hematol. 2022 Jan 26. doi: 10.1002/ajh.26479.
    >> Share

  239. IJURKO C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A, et al
    A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival.
    Am J Hematol. 2022 Jan 24. doi: 10.1002/ajh.26477.
    >> Share

  240. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    >> Share

  241. ROSSI M, Nizzoli ME, Galli A, Roncoroni E, et al
    Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
    Am J Hematol. 2022 Jan 18. doi: 10.1002/ajh.26469.
    >> Share

  242. DAHLEN T, Edgren G, Ljungman P, Flygt H, et al
    Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
    Am J Hematol. 2022 Jan 11. doi: 10.1002/ajh.26463.
    >> Share

  243. JELLOUL FZ, Yang R, Wang P, Garces S, et al
    Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis.
    Am J Hematol. 2022 Jan 6. doi: 10.1002/ajh.26457.
    >> Share

  244. PATNAIK MM, Tefferi A
    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26455.
    >> Share

  245. REVILLE PK, Sasaki K, Kantarjian HM, Daver NG, et al
    Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26451.
    >> Share

  246. NUMAN Y, Abdel Rahman Z, Grenet J, Boisclair S, et al
    Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26447.
    >> Share

  247. NAGLER A, Labopin M, Craddock C, Socie G, et al
    Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26442.
    >> Share

  248. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.
    >> Share

    December 2021
  249. DAVIDS MS, Shadman M, Parikh SA, Ujjani C, et al
    A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26444.
    >> Share

  250. VISENTIN A, Mauro FR, Cibien F, Vitale C, et al
    Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26437.
    >> Share

  251. SEGOT A, Stalder G, de Leval L, Solly F, et al
    Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
    Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26436.
    >> Share

  252. FORTES BH, Dalvin LA, Hogan WJ, Patnaik MM, et al
    Isolated T-cell acute lymphoblastic leukemic optic disc infiltration.
    Am J Hematol. 2021;96:1717-1718.
    >> Share

    November 2021
  253. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
    Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
    >> Share

  254. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
    Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
    >> Share

  255. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    >> Share

    October 2021
  256. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    >> Share

  257. TROUSSARD X, Maitre E, Cornet E
    Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
    >> Share

  258. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
    Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
    >> Share

  259. ZHANG Y, Li X, Weng X, Shen Y, et al
    Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
    Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
    >> Share

  260. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    >> Share

  261. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    >> Share

  262. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    >> Share

    September 2021
  263. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
    >> Share

    August 2021
  264. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
    Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
    >> Share

  265. ZHOU B, Chu X, Tian H, Liu T, et al
    The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
    Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
    >> Share

  266. ZHANG M, Xiao H, Shi J, Tan Y, et al
    Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
    Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
    >> Share

  267. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
    Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
    >> Share

  268. CHEN Z, Song J, Wang W, Bai J, et al
    A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
    >> Share

    July 2021
  269. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    >> Share

  270. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    >> Share

  271. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    >> Share

  272. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    >> Share

  273. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    >> Share

  274. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    >> Share

  275. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    >> Share

  276. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    >> Share

    June 2021
  277. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    >> Share

  278. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    >> Share

  279. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    >> Share

  280. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    >> Share

    May 2021
  281. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    >> Share

  282. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    >> Share

  283. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    >> Share

  284. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    >> Share

  285. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    >> Share

  286. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    >> Share

  287. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    >> Share

  288. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    >> Share

  289. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    >> Share

    April 2021
  290. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    >> Share

  291. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    >> Share

  292. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    >> Share

  293. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    >> Share

  294. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    >> Share

  295. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    >> Share

  296. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    >> Share

  297. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    >> Share

  298. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    >> Share

    April 2020
  299. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    >> Share

  300. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016